Overview Weekly Versus 3-Weekly Docetaxel Plus Cisplatin for Advanced NSCLC Status: Completed Trial end date: 2006-10-01 Target enrollment: Participant gender: Summary To evaluate the toxicity and efficacy of docetaxel and cisplatin combination on two schedules in patients with previously untreated, advanced NSCLC. Phase: Phase 2 Details Lead Sponsor: Gachon University Gil Medical CenterTreatments: CisplatinDocetaxel